Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?

A narrative systematic review of the evidence base

**INTRODUCTION**

Hepatitis C virus (HCV) infection is a silent epidemic; late effects of chronic hepatitis C (CHC) can include end-stage liver disease and require transplantation, as well as hepatocellular carcinoma, which becomes evident approximately 20–30 years after the infection has been acquired. It is estimated that 260 000 people have acquired HCV in the UK, of whom 215 000 have CHC; intravenous drug use is by far the most common route of acquisition.

The World Health Organization gives the global prevalence for hepatitis C exposure as 3%, with 170 million people affected and 3–4 million new infections annually.

Effective treatment exists in the form of weekly injections of pegylated interferon α-2a and 2b with daily, oral ribavirin; however, the patient group most likely to acquire the HCV through drug use is the group least likely to engage with secondary care for treatment. This poor engagement is multifactorial, but chaotic lifestyles and social exclusion are likely contributors.

Furthermore, in the UK and US there are insufficient numbers of consultants and nurse specialists in infectious diseases, hepatology, and gastroenterology to cope with the enormous numbers of patients who have CHC. The opportunity to treat hard-to-reach patients for CHC in prison has been recognised for several years. Skipper et al reported their evaluation of a prison outreach clinic in 2003, concluding that there was an opportunity to treat patients, but low uptake and a large proportion of exclusions under the then-current guidelines meant the impact was limited. However, the 2013 Health Protection Agency (HPA) report recommends that testing and treatment in prisons be strengthened.

Primary care has successfully taken the lead on a number of chronic diseases such as diabetes, chronic obstructive pulmonary disease, and asthma, while shared care for disease-modifying, antirheumatic drugs has placed more responsibility on GPs for blood-test monitoring of drugs with potentially dangerous toxicity. Such developments in community-care delivery suggest that, with suitable training and support, GPs are able to support secondary care colleagues by taking over the care of selected cases of many other chronic conditions, thereby increasing the availability of treatment for hard-to-reach groups.

As early as 2001, Kivlahan and Chavey suggested that, in view of the size of the HCV epidemic, treatment of hepatitis C would become a routine aspect of primary care. Budd and Robertson endorsed this view in the UK in 2005, suggesting that increased screening and diagnosis would swamp the current secondary care-based services.

Further barriers to offering treatment in secondary care have been identified as homelessness, poverty, lack of information about the benefits of treatment, chaotic...
How this fits in

The burden of liver disease is increasing in the UK and increasing prevalence of hepatitis C (HCV) is a recognised contributor to this trend. Current secondary care provision is difficult to access for a number of high risk groups and is under-resourced to tackle the estimated 215,000 patients with chronic HCV. Primary care is well-placed to offer support and this paper brings together the international experience of treating chronic HCV in the primary care setting.

Over the past 20 years in the number of GPs in the UK taking on a large part of the workload that relates to the management of substance misuse and opioid substitutes increasingly being prescribed in the primary care setting.12

Awareness has further been raised in primary care through the publication of guidance documents such as the Department of Health’s 2004 Hepatitis C: Essential Information for Professionals and Guidance on Testing13 and the 2007 Substance Misuse Management in General Practice (SMMGP) Guidance for the Prevention, Testing, Treatment and Management of Hepatitis C in Primary Care,14 which have informed primary care practitioners about hepatitis C. With such an increase in educational and awareness-raising activity in the management of blood-borne viruses in primary care, it was considered appropriate to undertake a systematic review to identify empirical and descriptive research that evidences the delivery of antiviral therapy in primary care throughout the international community.

METHOD

Search strategy

The medical databases Medline, Cinahl, PsycINFO, Cochrane, Web of Science, and Embase were searched using the umbrella search terms ‘hepatitis C, ribavirin and pegylated interferon, primary care, family practice, general practice’. A full copy of the search strategy is available from the authors on request. The databases were searched from 1 January 2000 to 13 July 2011 and, following initial peer-reviewer comments, re-run from 13 July 2011 to 20 June 2013. An example of one search strategy is given in Box 1.

Inclusion criteria

Papers dealing directly with hepatitis C drug treatment with pegylated interferon and ribavirin in primary care and primary care management of adverse effects during antiviral therapy were included. This included papers where antiviral treatment for hepatitis C was either initiated or maintained by GPs in the community [that is, non-specialist settings, which include mainstream general practice, GP-led prison services, or GP-led community drug services].

Exclusion criteria

Papers that were published pre-2000 were excluded because combination treatment was only licensed in 1998 and antiviral treatment was exclusively a specialist role.
Papers were also excluded if they:

- dealt exclusively with antiviral treatment in secondary care;
- dealt with interferon monotherapy or combination therapy, in which the interferon was not pegylated; or
- evaluated specialist-only treatment provision in the primary care setting.

Following peer-review comments, papers in which the outcome was changes in either GP knowledge or attitudes towards provision of antiviral treatment for hepatitis C were also excluded.

**Study selection**

Using inclusion and exclusion criteria, identified abstracts were assessed for relevance independently by two of the researchers; discrepancies were resolved by consensus between all three researchers. Following this process, full papers were retrieved for review by one of the researchers. Papers were considered as empirical research, descriptive research, commentary, or opinion pieces. Commentary and opinion pieces were excluded so that only empirical and descriptive research findings were included in the final review (Table 1). Relevant journals were hand-searched for pertinent articles and reference lists of these were reviewed for additional relevant papers. Box 2 highlights the criteria used to assess the quality of the evidence.

**RESULTS**

As highlighted in Figure 1, a total of 683 abstracts were identified using the search terms, including 33 duplicates. Of these, 573 were excluded by consensus between the authors and 77 papers were obtained in full for review. Sixteen papers were included in the review (Table 1). Primary outcomes measured included treatment initiation, maintenance or completion, or sustained virologic response (SVR). Twelve papers related to the mainstream primary care setting, three to treatment provision in the custodial setting, and one to both mainstream primary care and custodial provision.

**Antiviral treatment provision in the primary care setting**

Four Canadian studies have demonstrated

![Figure 1. Flowchart showing process of retrieval of papers included in the systematic review.](image-url)
<table>
<thead>
<tr>
<th>Authors</th>
<th>Demographics</th>
<th>Methodology</th>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen SA, et al(^{27})</td>
<td>US: 93 prisoners Rhode Island Correctional Facility</td>
<td>Retrospective, descriptive observational study</td>
<td>HCV RNA levels 6 months after treatment using intention to treat analysis</td>
<td>SVR rates similar to published data 44% (70% of all treated cases were genotype 1). Correctional setting provides an opportunity to safely treat patients with HCV</td>
</tr>
<tr>
<td>Arora S, et al(^{27})</td>
<td>US: New Mexico Health Sciences Center developed the ECHO, a telehealth training and support programme for primary care.</td>
<td>Prospective survey</td>
<td>Changes in primary care physician knowledge (self-rated), self-efficacy and professional satisfaction and hepatitis C antiviral treatment activity following participation in co-managed clinics after 6 months participation in ECHO. 415 teleclinics at 21 sites; &gt;5000 patients</td>
<td>57.5% SVR at specialist clinics and 58.2% at primary care clinics (0.7% difference in rate, 95% CI = –9.2 to 10.7, (P = 0.89)). 13.7% had serious adverse event at specialist clinics versus 6.9% at primary care clinics ((P = 0.02), CI not stated). In 8.9% specialist versus 4.2% primary care clinics adverse events led to termination of treatment ((P = 0.05) by univariate analysis, CI not stated; differences between the groups for the variables of age, sex, ethnic background and body mass index)</td>
</tr>
<tr>
<td>Arora S, et al(^{27})</td>
<td>US: 407 patients across 21 specialist and primary care clinic (rural and prison) sites</td>
<td>Prospective cohort study</td>
<td>SVR</td>
<td>SVR treatment completion rates 78.7% treatment completion rate Overall SVR 66.3% SVR versus intention to treat 51.8% (95% CI = 43.1 to 62.1%)</td>
</tr>
<tr>
<td>Charlebois A, et al(^{19})</td>
<td>Canada: 129 patients who attended three community-based health centres with on-site multidisciplinary team including GPs</td>
<td>Prospective cohort study</td>
<td>SVR</td>
<td>Treatment initiated on 24 patients and 71% (17) achieved SVR. SVR 91% (11) genotype 2 and 3; 54% (7) genotype 1. By multivariate analysis being housed was significantly associated with initiating treatment ((P &lt; 0.05), OR 6.22, 95% CI = 1.54 to 25.11)</td>
</tr>
<tr>
<td>Farley J, et al(^{28})</td>
<td>Canada: 114 male prisoners in a prisoner correctional facility in BC, Canada</td>
<td>Retrospective cohort study</td>
<td>SVR treatment completion rates</td>
<td>45% response rate. 39 out of 40 prisoners offered screening. 85% (34 out of 40) of prisoners offered antiviral treatment for HCV</td>
</tr>
<tr>
<td>Gerlich MG, et al(^{17})</td>
<td>Switzerland: a standardised questionnaire was sent to 91 prisons in the German and Italian speaking parts in October 2004; 41 institutions (45%) answered the questionnaire</td>
<td>Cross-sectional survey</td>
<td>• Estimated prevalence of hepatitis and HIV • Screening • Treatment</td>
<td>80 patients referred 26% (21) received/receiving treatment; 25% (20) under evaluation for HCV treatment; 29% (23) lost to follow-up; 10% (8) treatment non indicated; 10% (8) already complete initiated treatment prior to attendance. Treatment initiators/completers had higher attendance versus those lost to follow-up (median attendance 22.7 meetings versus 3.4 in the lost to follow-up group (P &lt; 0.001), IQR 1–5) and were more likely to attend &gt;3 clinic visits (100%) versus 35% (P &lt; 0.001), IQR or CI not stated. 67% (12) achieved an end of treatment response</td>
</tr>
<tr>
<td>Grebely J, et al(^{17})</td>
<td>Canada: 80 patients attending an inner-city multidisciplinary healthcare team comprising primary care and secondary care clinicians</td>
<td>Prospective observational efficacy trial (service evaluation). Evaluate treatment initiation, completion rates and patients attending a weekly support group</td>
<td>End of treatment response (not SVR) using intention-to-treat analysis</td>
<td>... continued</td>
</tr>
<tr>
<td>Authors</td>
<td>Demographics</td>
<td>Methodology</td>
<td>Outcomes</td>
<td>Results</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------------------------------</td>
<td>------------------------------------</td>
<td>---------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Hill WD, et al</td>
<td>Canada: 1795 referrals 2001–2005; 363 commenced on treatment; 205 completions. Treatment given by public health nurses and local physicians</td>
<td>Retrospective cohort</td>
<td>SVR using intention-to-treat analysis</td>
<td>79% treatment completion. Overall SVR 61% (48% for genotype 1; 74% for genotype 2 or 3)</td>
</tr>
<tr>
<td>Jack K, et al</td>
<td>UK: Windmill project. 174 HCV antibody positive clients. 118 chronic HCV, 30 treated</td>
<td>Descriptive study</td>
<td>Referral rates; Treatment rates; Completion rates; SVR using intention-to-treat analysis</td>
<td>333 patients, 246 anti-HCV tests undertaken of which 174 (65%) anti-HCV positive and 124 HCV RNA positive. 43 fulfilled the treatment criteria and 30 initiated treatment. 21 completed treatment and 13 achieved an SVR. Drug users more likely to attend a community clinic (&gt;85%) than hospital (&lt;40%) during the same period (although more complex patients were referred to hospital and potential confounders not controlled for due to small sample size precluding analysis)</td>
</tr>
<tr>
<td>John-Baptiste A, et al</td>
<td>Canada: 109 clients treated between November 2002–January 2006. Care given by hepatitis nurse, psychologist, infectious diseases consultant and primary care physicians</td>
<td>Retrospective review of treatment</td>
<td>Treatment completion rates; Response rates [SVR] using intention to treat analysis</td>
<td>Treatment completion rates: 61% genotype 1; 74% genotype 2/3. Treatment response (51% genotype 1; 68% genotype 2/3) comparable with non-substance misusing populations (54% versus 57% [P = 0.98, CI not stated]). Positive urine alcohol screen prior to treatment associated with lower SVR rates 52% versus 72% [P = 0.07, CI not stated] as less likely to complete treatment. Treatment completion correlated strongly with SVR: OR 3.84 [P&lt;0.001, 95% CI = 2.44 to 13.9]</td>
</tr>
<tr>
<td>Khatiri K, et al</td>
<td>Connecticut, US: Replication of ECHO 22 Intervention at a primary care clinic</td>
<td>Descriptive pilot study</td>
<td>Engagement in antiviral treatment</td>
<td>At 6 months 48 patients engaged in treatment</td>
</tr>
<tr>
<td>Litwin AH, et al</td>
<td>US: 801 addiction medicine physicians' practices in managing chronic HCV: 34% psychiatrists; 17% internal medicine; 17% family medicine; 6% GPs</td>
<td>National survey</td>
<td>Proportion of practitioners: Vaccinating for hepatitis A and B; treating or referring HCV; directly treating HCV</td>
<td>55% response rate (419, 87% screened at least one injecting drug user for HCV antibodies and 61% screened most injecting drug users for HCV antibodies. Factors associated with screening for HCV antibodies: provision of primary medical care (AOR 3.18, 95% CI = 1.88 to 5.38); hospital affiliated setting (AOR 2.56, 95% CI = 1.50 to 4.37); non-profit or public setting (AOR 2.56, 95% CI = 1.50 to 4.37); Medics who provided primary care (AOR 1.87, 95% CI = 1.08 to 3.23); or currently checked for ≤15 patients (AOR 4.45, reported 95% CI = 2.57 to 2.70) mostly likely to refer. 9% of physicians directly offering treatment and only 1% of primary care physicians, but 31% of all physicians willing to treat if trained appropriately</td>
</tr>
<tr>
<td>Newmann AI, et al</td>
<td>Canada: 34 patients attending a community health clinic</td>
<td>Prospective cohort study</td>
<td>SVR</td>
<td>41% initiated treatment (14 of whom 78% [11] achieved ETR and 57% [8] achieved SVR)</td>
</tr>
</tbody>
</table>

... continued
the feasibility and effectiveness of community-based antiviral treatment provision among individuals who inject drugs. The largest study conducted by Hill et al evaluated the outcomes of treatment provision to 1795 individuals at four community centres in rural and small urban settings.15 Treatment was initiated to a total of 390 patients and outcomes were available for 205 patients. The overall SVR in these 205 patients was 61%. This study was a primary care model in that patients could self-refer into treatment; however, the paper was not explicit as to whether the physician involvement was by GPs or limited to specialist clinicians.

The following year, the second Canadian study conducted by John-Baptiste et al evaluated antiviral treatment provision in primary care-based community addiction-treatment centres.16 Key findings from a cohort of 109 patients demonstrated treatment completion rates of 61% and 74% for genotypes 1 or 4 and 2 or 3 respectively. Treatment response rates analysed by intention to treat were 51% and 68% for genotypes 1 or 4 and 2 or 3 respectively. Positive urine toxicology indicating use of illicit drugs in the 6 months prior to treatment was significantly associated with lower rates of treatment completion but not lower rates of SVR. A positive urine screen indicating the use of alcohol prior to therapy was associated with both lower rates of treatment completion and lower rates of response. The authors concluded that treatment completion and response rates were comparable to populations who do not misuse substances.

The finding of the feasibility of community-based treatment provision to those who inject drugs is confirmed by another Canadian study conducted by Grebely et al.17 Community-based treatment provision to such individuals was through a multidisciplinary team model comprising both primary and secondary care clinicians. Of the participants, 65% achieved an end of treatment response (ETR) despite the fact that three-quarters of all recruited patients reported ongoing drug use. In those who completed treatment, virological response at the end of treatment was 67%, 100%, and 57% for genotypes 1, 2, and 3 respectively. However, numbers were small as only 18 patients were recruited to the study.

Newman et al carried out a Toronto-based study in 2011 of ‘high-risk, marginalised, and traditionally underserved’ patients with HCV. They treated 14 out of a sample of 34 patients and, of these, 11 completed treatment with eight achieving SVR. Again,
small numbers was a feature of the study, but further evidence of the potential for success was demonstrated.18

The evidence would suggest that support needs to be offered to those who use drugs to engage with, and remain in, primary care-based treatment. Charlebois et al. reported the effects of peer support in a multidisciplinary team in Toronto.19 Of 110 eligible patients, treatment was initiated in 24; of these, 13 had genotype 1 HCV and seven (54%) achieved SVR compared with 10 (91%) out of 11 with genotype 2 or 3. The authors concluded that active drug use was not necessarily a contraindication to HCV treatment when supported with psychosocial support and accessible health care.19

In addition to psychosocial support, it would appear that linking treatment to opioid maintenance therapy increases treatment uptake and completion. Seidenberg et al. showed that it was feasible for GPs offering opiate substitution treatment to provide antiviral treatment to patients with HCV.20 Antiviral therapy was provided to 35 suitable patients out of a total of 85 who were receiving opiate replacement therapy. Forty patients declined the offer of treatment and the remaining 10 were deemed unfit for other health reasons. An SVR rate of 71% was achieved.

Although these studies provide support for the provision of antiviral treatment in the primary care setting, the need for prior training is a necessary prerequisite. Litwin et al. found that, although only 1% of primary care physicians were treating CHC, 13% were willing to do so with appropriate training.21 Novel ways of training primary care staff are emerging. Through Project ECHO (Extension for Community Healthcare Outcomes), the University of New Mexico in the US evaluated a teleconferencing approach whereby primary care clinicians meet weekly with specialists via teleconference.22 Support is provided to facilitate primary care practitioners in offering antiviral treatment to patients who are hepatitis C positive. Primary care practitioner self-rated knowledge and treatment activity was surveyed in 415 teleclinics at 21 sites. Results showed a statistically significant increase in perceived competence scores during the course of the project. Clinical outcomes of Project ECHO were reported in 2011,23 in total, 407 patients treated for hepatitis C resulted in a 58.2% overall SVR rate compared with a rate of 57.5% that had been reported at the University of New Mexico’s specialist hepatitis C clinic. The authors concluded that implementation of this model would allow other states and nations to treat a greater number of patients infected with HCV than they are currently able to treat. The Project ECHO model was replicated as a pilot project in Connecticut, US, with the primary outcome being treatment engagement; 48 patients were engaged in treatment at the 6-month time-point.24

In 2008, the Windmill Project in the UK reported on the community-based treatment of 30 patients with CHC. The service was based around a specialist nurse from secondary care working with drug workers and GPs. The evaluation found that patients were twice as likely to attend their antiviral treatment appointments at the primary care clinic as those referred to secondary care during the same period.25 Similar SVR rates were reported, although these were not statistically significant due to low numbers.

The possible effectiveness of a specialist nurse to support GPs was highlighted in the study by Wilkie.26 In this model, an experimental, nurse-led community hepatitis C service was conducted; it was funded by practice-based commissioning savings and based in three general practices in Liverpool. An SVR rate of 46% was reported with 19% of participants failing to complete treatment. At the time the paper was submitted, 17% of patients were still in treatment or awaiting results. The remaining 18% were lost to follow-up (3%), relapsers (5%) or other outcome (10%).

Antiviral treatment provision in custodial settings

Service evaluations of prison-based antiviral treatment have been conducted in the US27 and Canada,28 where SVR rates using intention-to-treat analysis was 48% (70% genotype 1) and 51.8% respectively. Both studies concluded that correctional facilities provided an ideal opportunity to diagnose and treat patients with CHC in combination with preventative measures.

A repeated cross-sectional survey of treatment provision in more than 80 French prisons was conducted by Remy in 2000 and 2003; over that time, provision increased from 164 patients receiving treatment in 2000 to 297 patients receiving treatment in 2003.27 The number of prisons offering ‘no treatment’ reduced from 44% in 2000 to 29% in 2003.29

A cross-sectional survey of treatment coverage in Swiss prisons was conducted by Gerlich et al in 2004.30 In total, 41 prisons
responded to the survey and key findings were that antiviral treatment provision was possible in 85% of them. However, treatment discontinuation on release was identified as a significant barrier to treatment completion. In response to this barrier, five institutions reported not offering antiviral therapy to patients who had less than 6 months of their sentence to serve due to the high risk of completion failure.

**DISCUSSION**

**Summary**

The HPA recommend in its 2013 report: ‘Commissioners should consider expanding provision of treatment in non-traditional settings, including primary care, drug treatment settings and prisons, to make treatment more accessible for individuals and thereby reduce the potential for transmission’.1

There is published evidence that the current provision for delivering antiviral treatment to patients with CHC is inadequate in many countries around the world, including the UK. Several commentators have recommended that antiviral therapy can, and should, be delivered in the multidisciplinary primary care setting when focused on areas of high prevalence of HCV.4,8-10,15,17,27-28 The findings of the current review have suggested that such primary care-based treatment is feasible with support from specialists. Such a model has treatment outcomes that are equivalent with secondary care services. However, providing such a model across the whole of the primary care treatment system will require an extensive programme of education of GPs. There have been several studies showing the non-inferiority of antiviral therapy in primary care15,16,25 but further studies are needed to demonstrate the non-inferiority of SVR from antiviral therapy delivered in each of the various primary care environments, compared with secondary care. Furthermore, the heterogeneous nature of primary care will require the comparison of the various piloted models of care for cost-effectiveness in each setting so that appropriately evidenced business cases may be produced for these new services. This review has highlighted recent evidence from the UK of savings from practice-based commissioning being used to provide specialist-nurse support for GPs willing to prescribe.26

Before primary care-based antiviral treatment for CHC can become a mainstream reality in the UK, further training is required to increase GPs and other primary care workers’ knowledge of hepatitis C management, and referral pathways with appropriate exclusion criteria need to be developed. It could be that novel approaches to training need to be considered, particularly for GPs working in rural settings. For example, US research compared the impact of videoconferencing with standard lecturing on 175 primary care providers (primary care physicians, nurses, physicians assistants, and nurse practitioners) using a 10-point quiz before and after videoconferencing. All groups demonstrated a statistically significant improvement in their scores post videoconferencing leading the authors to conclude that such training ‘has the potential to eliminate the geographical and economic barriers to professional education’ for rural practitioners or those who are otherwise isolated.21

The RCGP has successfully delivered certificate courses in the detection and diagnosis of hepatitis B and C.11 The Certificate 2 course is delivered through a learning log, which is based on case studies and clinic attendances with specialist mentors and tutors. Successful completion of the course will give primary care practitioners the confidence to support secondary care colleagues in delivering treatment to the most appropriate cases. In time, this confidence may translate into local antiviral treatment services based in primary care, but there will need to be robust links with specialist clinics for clinical governance purposes.

In the past 12 months, new ‘triple therapy’ treatment protocols have been licensed and appraised by the then National Institute of Health and Clinical Excellence [NICE]32,33 with the potential for new side-effect profiles, including rashes and marked anaemia. The addition of protease inhibitors telaprevir and boceprevir to treatment protocols for genotype 1 HCV means that close haematological monitoring is of even more importance than with pegylated interferon and ribavirin alone. As such, an ongoing educational and competency framework must be developed to permit the safe and effective delivery of current antiviral therapies in the primary care setting. The Department of Health document Implementing Care Closer to Home: Convenient Quality Care for Patients34 and its programme of re-accreditation would present an ideal framework for accreditation for practitioners with special interest in viral hepatitis.
The findings of this review have also highlighted that custodial settings can be an ideal place to initiate antiviral treatment. However, there is a risk of discontinuation on release from prison; so much so that antiviral treatment can be withheld from patients on short sentences. There is a pressing need to develop and evaluate treatment models that allow for the initiation of antiviral treatment in custodial settings, which is continued in the community at the point of the patient’s release from prison. In England, an estimated 27,500 patients were treated between 2006 and 2011 with pegylated interferon as part of NICE-recommended combination therapy; this equated to treating approximately 3% of those who are chronically infected per year. France has recorded higher treatment rates, including 14% across a number of French prisons. Strengths and limitations

At present, there is little published evidence about GPs delivering antiviral therapy, particularly in the UK. Numbers treated in studies such as the Windmill Project were small, so lacked statistical power. The strengths of this review were the synthesis for the first time of the literature pertaining to the feasibility of providing antiviral treatment for hepatitis C in the primary care setting. A comprehensive systematic review of the key databases was undertaken.

Comparison with existing literature

The findings of this systematic review pertaining to the feasibility of such primary care provision concur with both opinion pieces expressing the potential of primary care to increase availability of this important treatment and also wider empirical literature highlighting that with training GPs feel more confident in offering this treatment.

Implications for practice

The findings from this review of the international evidence base would suggest that primary care services deliver results equivalent to secondary care among hard-to-reach groups. Further adequately powered studies will help to underpin the work already published. There are likely to be a variety of primary care models delivering such antiviral treatment though all will require support from local specialist services. For experienced GPs who have large numbers of drug using patients (for example those working in prison or primary care community drug service settings) they are likely to initiate, continue and complete prescribing regimes for large numbers of patients with support in the form of clinical supervision from specialist services. However for GPs in mainstream practice with small numbers of drug using patients, the treatment model is more likely to be akin to traditional shared care models for other chronic diseases (for example, provision of insulin to those with diabetes, or disease modifying antirheumatic drugs for rheumatoid arthritis). However regardless of the model, it is hoped that this review will encourage more GPs to become involved in this important and rapidly developing area of health care.

Funding

Dr Iain F Brew received a flexibility and sustainability research grant through the research team at Leeds Community Healthcare NHS Trust to cover backfill for one weekly clinical session. The trust acted as sponsor for the research project.

Provenance

Freely submitted; externally peer reviewed.

Competing interests

Dr Iain F Brew was involved in the development of the Royal College of General Practitioners certificates in hepatitis B and C and received payments for his work as tutor and examiner. He has also received honoraria from Janssen for delivering meetings about hepatitis C in the UK. All other authors have declared no competing interests.

Acknowledgements

The authors gratefully acknowledge Philippa Hearty, Beverley Berry, and Richard Daly of the RCGP library, as well as Helen Swales and staff at the library services of Leeds Community Healthcare NHS Trust for their assistance in retrieving the documents for this literature review.

Discuss this article

Contribute and read comments about this article on the Discussion Forum: http://www.rcgp.org.uk/bjgp-discuss
REFERENCES


